Announcements Trials
Browse Landscape

Phase

Phase 1/2 14Phase NA 7Phase 2 7Phase 1 5Phase 3 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Older Patients 1Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Promyelocytic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Diseases 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 13Methotrexate 12Cytarabine 11Dexamethasone 10Vincristine 9Etoposide 7Radiotherapy 6Mercaptopurine 6Daunorubicin 6Asparaginase 6pegaspargase 5blinatumomab 5Dasatinib 5Prednisone 4Methylprednisolone 4Filgrastim 4Doxorubicin 4ruxolitinib 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Busulfan 3Antilymphocyte Serum 3venetoclax 2fludarabine phosphate 2fludarabine 2etoposide phosphate 2calaspargase pegol 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × venetoclax × Clear all
NCT06855810 2025-08-26

CCCG-TALL-2025

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
610 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06764238 2025-02-07

CCCG-I/HR-ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
1,800 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡